Table 1. Baseline characteristics of randomized trials included in the meta-analysis.
In grey the studies excluded from the relative risk (RR) analysis due to the presence of an active control arm.
| Author and Year | Ref. | Phase | Malignancy | Treatment | N. subjects | Jadad scale | ||
|---|---|---|---|---|---|---|---|---|
| Targeted therapy | Control Arm | Targeted therapy | Control Arm | |||||
| Wu et al. 2014 | 18 | 3 | NSCLC | Afatinib | CDDP + GEM | 239 | 113 | 3 |
| Llovet et al. 2013 | 19 | 3 | HCC | Brivanib | Placebo | 263 | 132 | 4 |
| Johnson et al. 2013 | 20 | 3 | HCC | Brivanib | Sorafenib | 575 | 575 | 4 |
| Siu et al. 2013 | 21 | 3 | Colorectal cancer | Brivanib + Cetuximab | Cetuximab | 372 | 373 | 3 |
| Burtness et al. 2005 | 22 | 3 | HN tumors | CDDP + Cetuximab | CDDP | 58 | 58 | 5 |
| Lordick et al. 2013 | 23 | 3 | Gastric cancer | CDDP + Capecitabine + Cetuximab | CDDP + Capecitabine | 446 | 436 | 3 |
| Crosby et al. 2013 | 24 | 2/3 | Oesophageal cancer | Chemoradiotherapy +Cetuximab | Chemoradiotherapy | 129 | 129 | 3 |
| Gaafar et al. 2011 | 25 | 3 | NSCLC | Gefitinib | Placebo | 85 | 86 | 4 |
| Argiris et al. 2013 | 26 | 3 | HN tumors | DTX + Gefitinib | DTX | 124 | 129 | 4 |
| Cainap et al. 2015 | 27 | 3 | HCC | Linifanib | Sorafenib | 510 | 519 | 3 |
| Sternberg et al. 2010 | 28 | 3 | RCC | Pazopanib | Placebo | 290 | 145 | 4 |
| Flaherty et al. 2013 | 29 | 3 | Melanoma | CBP + PTX + Sorafenib | CBP + PTX | 393 | 397 | 4 |
| Ramalingam et al. 2010 | 30 | 2 | NSCLC | CBP + PTX + Vorinostat | CBP + PTX | 62 | 32 | 3 |
Legend. CBP: Carboplatin, CDDP: Cisplatin, DTX: Docetaxel, GEM: Gemcitabine, HCC: hepatocellular carcinoma, HN: head and neck, NSCLC: non-small cells lung cancer, PTX: Paclitaxel, RCC: renal cell carcinoma.